» Articles » PMID: 36133739

The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2022 Sep 22
PMID 36133739
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system and has a 5-year overall survival rate of 14.1%. Many HCC patients are diagnosed at an advanced stage, and thus early screening is essential for reducing the mortality of HCC. In addition to commonly used detection indicators such as serum alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) and abnormal prothrombin (protein induced by vitamin K absence II, PIVKA-II), liquid biopsy techniques have been demonstrated to have diagnostic value in HCC detection. Compared with invasive procedures, liquid biopsy can detect circulatory metabolites of malignant neoplasms. Liquid biopsy techniques can detect circulating tumor cells, circulating tumor DNA, circulating RNA and exosomes and have been used in the early screening, diagnosis and prognostic evaluation of HCC. This paper reviews the molecular biological characteristics and application of different liquid biopsy techniques, and aim to highlight promising biomarkers that may be feasible options for early-stage HCC evaluation to improve early screening in populations at high risk for HCC.

Citing Articles

Silencing NCAPD3 Inhibits Tumor Growth and Metastasis in Hepatocellular Carcinoma by Suppressing PI3K-AKT Signalling Pathway.

Lv J, Gan F, Li M, Yin Q Curr Med Sci. 2025; .

PMID: 40029498 DOI: 10.1007/s11596-025-00026-2.


Liquid Biopsy in the Clinical Management of Cancers.

Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).

PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.


Advancements and Applications of Liquid Biopsies in Oncology: A Narrative Review.

Noor J, Chaudhry A, Noor R, Batool S Cureus. 2023; 15(7):e42731.

PMID: 37654932 PMC: 10466971. DOI: 10.7759/cureus.42731.

References
1.
. [Expert consensus on early screening strategies for liver cancer in China]. Zhonghua Gan Zang Bing Za Zhi. 2021; 29(6):515-522. DOI: 10.3760/cma.j.cn501113-20210605-00264. View

2.
Qi L, Xiang B, Wu F, Ye J, Zhong J, Wang Y . Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Cancer Res. 2018; 78(16):4731-4744. DOI: 10.1158/0008-5472.CAN-17-2459. View

3.
Kanwal F, Singal A . Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology. 2019; 157(1):54-64. PMC: 6636644. DOI: 10.1053/j.gastro.2019.02.049. View

4.
Yeo W, Wong N, Wong W, Lai P, Zhong S, Johnson P . High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005; 25(2):266-72. DOI: 10.1111/j.1478-3231.2005.01084.x. View

5.
Xie Y, Yao Q, Butt A, Guo J, Tian Z, Bao X . Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther. 2014; 15(9):1248-55. PMC: 4128867. DOI: 10.4161/cbt.29688. View